A Brisbane research project that began during the Covid-19 pandemic based on century-old human tissue has expanded into world-leading research on how to manage the treatment of cancers. The "back to the future" project, led by Professor John Fraser, De Arutha Kulasinghe and Associate Professor Kirsty Short, works on extracting data from tissue samples collected during the 1918 Spanish flu pandemic.

De Motu Cordis (DMC) is pleased to acknowledge and enthusiastically commends the recent U.S. FDA approval of ARS Pharma's Neffy®, the first-ever needle-free intranasal epinephrine delivery device for the treatment of anaphylaxis.

De Motu Cordis (DMC) today announced plans for the next stage of development with its Contract Development and Manufacturing Organization (CDMO) partner, Catalent, at Catalent’s Boston, Morrisville and San Diego sites.